We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. Show more
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (โBriaProโ or the โCompanyโ), a pre-clinical stage immunotherapy company developing binding agents and...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
BriaCell reports influx of cancer fighting CD8+ โkillerโ T cell into metastatic breast cancer tumors and lymph organs turning โColdโ tumors and lymph nodes โHotโ on ImmunoPET imaging in cancer...
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCellโs pivotal Phase 3 study of Bria-IMTโข plus an immune check point inhibitor in metastatic...
SABCSยฎ โSpotlightโ poster to be presented on Wednesday, December 11, 2024 7:00 AM โ 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer...
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.183152 | -31.0505008036 | 0.589852 | 0.65 | 0.395 | 1915654 | 0.47721372 | CS |
4 | -0.2723 | -40.1030927835 | 0.679 | 0.679 | 0.395 | 1347814 | 0.55624402 | CS |
12 | -0.4125 | -50.3540039062 | 0.8192 | 1.26 | 0.395 | 1505809 | 0.80105868 | CS |
26 | -0.6533 | -61.6320754717 | 1.06 | 1.96 | 0.395 | 3122373 | 0.72932097 | CS |
52 | -4.4133 | -91.5622406639 | 4.82 | 4.89 | 0.395 | 1632466 | 0.78048004 | CS |
156 | -7.7933 | -95.0402439024 | 8.2 | 12.09 | 0.395 | 755751 | 2.56731295 | CS |
260 | -3.8333 | -90.4080188679 | 4.24 | 12.47 | 0.395 | 1146366 | 4.48906458 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions